Second-line treatment of advanced measurable ovarian cancer with iproplatin: A Southwest oncology group study

Geoffrey Weiss, Stephanie Green, David S Alberts, James Tate Thigpen, Harry E. Hines, Karl Hanson, H. Irving Pierce, Laurence H. Baker, John Wendall Goodwin

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

105 patients with advanced ovarian cancer previously treated with cisplatin or carboplatin were entered into a study of iproplatin as second-line therapy. Patients were either clinically resistant to cisplatin or carboplatin, or had relapsed after complete response to these agents. Patients were treated intravenously at an initial dosage of 270 mg/m2 with dosage adjustments to 340, 200 or 135 based on observed toxicity. Of 101 eligible patients, 7 responses (3 complete, 4 partial; 12%) were observed in 60 patients resistant to cisplatin. 2 partial responses (11%) occurred in 18 patients resistant to carboplatin. 2 complete and 3 partial responses were observed in 19 patients (26%) previously treated with but not resistant to cisplatin. Response durations were 2-20 months. Toxicities of iproplatin included thrombocytopenia in 93% of patients, leukopenia in 76% of patients, anaemia in 68% of patients, and diarrhoea in 40% of patients. Thus iproplatin shares cross-resistance with cisplatin and carboplatin in the treatment of ovarian cancer and is not recommended as an effective second-line agent for platinum-resistant ovarian cancer.

Original languageEnglish (US)
Pages (from-to)135-138
Number of pages4
JournalEuropean Journal of Cancer and Clinical Oncology
Volume27
Issue number2
DOIs
StatePublished - 1991

Fingerprint

Ovarian Neoplasms
Cisplatin
Carboplatin
Therapeutics
iproplatin
Leukopenia
Platinum
Thrombocytopenia
Anemia
Diarrhea

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Second-line treatment of advanced measurable ovarian cancer with iproplatin : A Southwest oncology group study. / Weiss, Geoffrey; Green, Stephanie; Alberts, David S; Thigpen, James Tate; Hines, Harry E.; Hanson, Karl; Irving Pierce, H.; Baker, Laurence H.; Goodwin, John Wendall.

In: European Journal of Cancer and Clinical Oncology, Vol. 27, No. 2, 1991, p. 135-138.

Research output: Contribution to journalArticle

Weiss, Geoffrey ; Green, Stephanie ; Alberts, David S ; Thigpen, James Tate ; Hines, Harry E. ; Hanson, Karl ; Irving Pierce, H. ; Baker, Laurence H. ; Goodwin, John Wendall. / Second-line treatment of advanced measurable ovarian cancer with iproplatin : A Southwest oncology group study. In: European Journal of Cancer and Clinical Oncology. 1991 ; Vol. 27, No. 2. pp. 135-138.
@article{ce844405f4dd431cb589171aa37564e7,
title = "Second-line treatment of advanced measurable ovarian cancer with iproplatin: A Southwest oncology group study",
abstract = "105 patients with advanced ovarian cancer previously treated with cisplatin or carboplatin were entered into a study of iproplatin as second-line therapy. Patients were either clinically resistant to cisplatin or carboplatin, or had relapsed after complete response to these agents. Patients were treated intravenously at an initial dosage of 270 mg/m2 with dosage adjustments to 340, 200 or 135 based on observed toxicity. Of 101 eligible patients, 7 responses (3 complete, 4 partial; 12{\%}) were observed in 60 patients resistant to cisplatin. 2 partial responses (11{\%}) occurred in 18 patients resistant to carboplatin. 2 complete and 3 partial responses were observed in 19 patients (26{\%}) previously treated with but not resistant to cisplatin. Response durations were 2-20 months. Toxicities of iproplatin included thrombocytopenia in 93{\%} of patients, leukopenia in 76{\%} of patients, anaemia in 68{\%} of patients, and diarrhoea in 40{\%} of patients. Thus iproplatin shares cross-resistance with cisplatin and carboplatin in the treatment of ovarian cancer and is not recommended as an effective second-line agent for platinum-resistant ovarian cancer.",
author = "Geoffrey Weiss and Stephanie Green and Alberts, {David S} and Thigpen, {James Tate} and Hines, {Harry E.} and Karl Hanson and {Irving Pierce}, H. and Baker, {Laurence H.} and Goodwin, {John Wendall}",
year = "1991",
doi = "10.1016/0277-5379(91)90470-X",
language = "English (US)",
volume = "27",
pages = "135--138",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "2",

}

TY - JOUR

T1 - Second-line treatment of advanced measurable ovarian cancer with iproplatin

T2 - A Southwest oncology group study

AU - Weiss, Geoffrey

AU - Green, Stephanie

AU - Alberts, David S

AU - Thigpen, James Tate

AU - Hines, Harry E.

AU - Hanson, Karl

AU - Irving Pierce, H.

AU - Baker, Laurence H.

AU - Goodwin, John Wendall

PY - 1991

Y1 - 1991

N2 - 105 patients with advanced ovarian cancer previously treated with cisplatin or carboplatin were entered into a study of iproplatin as second-line therapy. Patients were either clinically resistant to cisplatin or carboplatin, or had relapsed after complete response to these agents. Patients were treated intravenously at an initial dosage of 270 mg/m2 with dosage adjustments to 340, 200 or 135 based on observed toxicity. Of 101 eligible patients, 7 responses (3 complete, 4 partial; 12%) were observed in 60 patients resistant to cisplatin. 2 partial responses (11%) occurred in 18 patients resistant to carboplatin. 2 complete and 3 partial responses were observed in 19 patients (26%) previously treated with but not resistant to cisplatin. Response durations were 2-20 months. Toxicities of iproplatin included thrombocytopenia in 93% of patients, leukopenia in 76% of patients, anaemia in 68% of patients, and diarrhoea in 40% of patients. Thus iproplatin shares cross-resistance with cisplatin and carboplatin in the treatment of ovarian cancer and is not recommended as an effective second-line agent for platinum-resistant ovarian cancer.

AB - 105 patients with advanced ovarian cancer previously treated with cisplatin or carboplatin were entered into a study of iproplatin as second-line therapy. Patients were either clinically resistant to cisplatin or carboplatin, or had relapsed after complete response to these agents. Patients were treated intravenously at an initial dosage of 270 mg/m2 with dosage adjustments to 340, 200 or 135 based on observed toxicity. Of 101 eligible patients, 7 responses (3 complete, 4 partial; 12%) were observed in 60 patients resistant to cisplatin. 2 partial responses (11%) occurred in 18 patients resistant to carboplatin. 2 complete and 3 partial responses were observed in 19 patients (26%) previously treated with but not resistant to cisplatin. Response durations were 2-20 months. Toxicities of iproplatin included thrombocytopenia in 93% of patients, leukopenia in 76% of patients, anaemia in 68% of patients, and diarrhoea in 40% of patients. Thus iproplatin shares cross-resistance with cisplatin and carboplatin in the treatment of ovarian cancer and is not recommended as an effective second-line agent for platinum-resistant ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026035859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026035859&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(91)90470-X

DO - 10.1016/0277-5379(91)90470-X

M3 - Article

C2 - 1827275

AN - SCOPUS:0026035859

VL - 27

SP - 135

EP - 138

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 2

ER -